By Sean Orr, M.D. | November 21, 2026 | Florida Doctor Magazine
Since January 2026, a Utah patient who needs a 90-day renewal of a blood pressure pill has been able to request it through an AI system instead of a visit. Utah’s Office of Artificial Intelligence Policy (OAIP) signed a sandbox agreement with the company Doctronic on October 24, 2025, and the state’s licensing division agreed not to enforce parts of its licensing and telehealth law against the tool. A licensed physician still authorizes every request. Florida has no statute, rule or sandbox that addresses AI renewing prescriptions, and its Attorney General has asked the Board of Medicine to look at AI and the unlicensed practice of medicine. A Florida practice should decide how AI enters its refill queue before a health system or payer decides for it.
What Utah Authorized, and What It Did Not
The agreement covers 30-, 60- or 90-day renewals of medications a clinician already prescribed, drawn from a list of 192 drugs. The state says the AI “will not issue new prescriptions, handle controlled or addictive substances, or make changes to treatment plans.” Doctronic must employ a licensed physician whose name appears on each renewal. Phase 2, where the AI would send renewals straight to the pharmacist, requires 250 fills in a drug group plus OAIP approval. The state says Phase 2 “has not been approved.” The first term ended October 24, 2026; the state still lists the pilot as active, and we could not confirm an extension.
What the Early Data Show
OAIP’s May 2026 report covers January through April. The AI recommended renewal in 72% of cases and the reviewing physician agreed 91% of the time. The other 28% were escalated, and physicians judged 69% of those escalations appropriate and 31% overly cautious. The data are Doctronic physicians’ own reviews, with no sample size given. OAIP has begun an independent review, says it still lacks strong evidence of benefit, and reports no serious safety incidents. A widely quoted 99.2% treatment-plan match in 500 urgent-care visits comes from an unreviewed preprint by Doctronic equity owners that measured no patient outcomes.
The Case Against, and the Case For
Utah’s Physicians Licensing Board wrote on April 20, 2026, in a letter KSL reported was signed by 11 of its 14 members, that it “was made aware of this agreement only after its implementation,” and recommended that the program “be immediately suspended pending further discussion.” Board chair Dr. Alan Smith told the Associated Press, “Just because something was prescribed before does not mean it’s appropriate now.” The American Medical Association told AP that “prescription renewals aren’t routine checkboxes.” The evidence is company-reported and small, a contract with a state office stands in for licensing law, the FDA told AP it has not authorized any AI chatbots, and Phase 2 would move the physician to review after the fact. The company’s ambitions also reach past Utah: co-CEO Matt Pavelle said in its March Series B release that “Health systems see us as infrastructure, the digital front door that routes their patients efficiently and keeps care in-network.”
Supporters make an equally serious case. Utah says renewals account for “roughly 80% of all medication activity,” and a missed renewal of an antihypertensive is where nonadherence and avoidable emergency visits begin, especially for rural and elderly patients. The design is narrow, with no controlled substances, new drugs or dose changes, and a physician approving every request in Phase 1. Reviewers found nearly a third of escalations overly cautious, which suggests a protocol that leans toward the physician. On April 21 the state declined to suspend the pilot, citing physician review of every refill.
Both positions hold some truth. AI that clears a clean renewal queue and flags the rest can extend a physician’s capacity while the physician’s judgment and signature stay in charge; the dispute is whether authority rests with the physician or a protocol. The evidence supports keeping physician review in the loop and publishing independent outcome data before oversight is reduced, and it does not yet support more than that.
Where Florida Stands
Section 458.305, Florida Statutes, defines the practice of medicine to include the “diagnosis, treatment, operation, or prescription for any human disease,” and practicing without a Florida license is a third-degree felony under sections 458.327 and 456.065. Section 456.47 limits telehealth providers to licensed or registered individuals. None of these mentions AI. Utah needed a sandbox because its licensing law would otherwise apply; Florida has no equivalent mechanism, and we draw no conclusion about whether any particular AI renewal would be lawful here.
The 2026 session did not change that, as our 2026 session wrap-up explains. SB 482, the AI Bill of Rights, passed the Senate 35-2 and died in the House; it covered government AI contracts and companion chatbots, not clinical tools. HB 527, barring AI as the sole basis for a claim denial, passed the House 108-0 and died in Senate Rules. The Senate’s 2027 bill list shows no AI health bill so far.
At a September press event, Attorney General James Uthmeier said he would work with the Board of Medicine on rules for AI chatbots and unlicensed practice, and FOX49 reported that he asked the Board to investigate AI platforms. “This is not a licensed doctor,” he said. The Board’s 2026-27 regulatory plan lists no AI rule. Tallahassee primary care physician Dr. Matthew Zaideman told FOX49, “AI is kind of the Wild West in general.” The issue joins the others on our Florida scope of practice and regulation hub.
Liability is unsettled. No Florida statute or appellate decision assigns responsibility when an AI tool makes a clinical call; what exists is malpractice law, Board discipline under section 458.331, the vendor contract and your policy. Our report on AI scribes and Florida’s recording law shows how an ordinary AI tool can raise an unplanned legal question.
Does Early Adoption Help Independent Physicians?
Some argue that independent physicians who adopt AI on their own terms will fare better than those who wait. Doctronic sells to health systems and payers, so a physician who waits may meet the tool as someone else’s contract term. But no published data compare independent and employed practices on AI adoption, outcomes or liability, so this is a reasoned position, not an evidence-based finding. Our Digital Health 50 guide shows which companies are already selling to Florida practices.
What Florida Physicians Should Do Now
- Ask your malpractice carrier, in writing, how it treats AI-assisted decisions. None of this constitutes legal advice, so have a health care attorney read the answer with your policy.
- Read any AI vendor contract for indemnity, permitted uses of patient data, and the licensed physician of record for each decision.
- Have staff work your refill queue from a written protocol, gathering the last visit date, labs due and interaction flags so you can approve renewals faster.
- Tell patients plainly when an AI tool is part of their care.
- Watch the Board of Medicine meeting on December 4, the 2027 session opening March 2, and Utah’s Phase 2 decision. Controlled-substance renewals by telehealth face their own deadline, covered in our DEA telehealth guide.
The Bigger Picture
The questions for our profession are who writes the protocol, who signs the renewal and who sees the outcome data. For our next report we will seek out a health-system informatics leader, the Florida Medical Association, a Board of Medicine member, an independent primary care owner and a pharmacist.
Frequently Asked Questions
Can AI renew prescriptions in Florida?
No Florida statute, Board of Medicine rule or state sandbox authorizes AI to renew prescriptions, and none addresses it directly. Florida defines prescribing as part of the practice of medicine, which requires a license. This is not legal advice; ask a health care attorney about any specific tool.
What does Utah’s Doctronic pilot cover?
Renewals of 30, 60 or 90 days for about 190 previously prescribed, non-controlled drugs. It does not start new medications or change doses, and a licensed physician’s name appears on every renewal.
Does a physician still approve every AI renewal in Utah?
Yes. The pilot remains in Phase 1, where a licensed practitioner authorizes every request. Utah’s pilot page says no drug group has been approved for Phase 2.
Has the Florida Board of Medicine acted on AI?
Not by rule. Attorney General James Uthmeier said in September that he would work with the Board on AI and unlicensed practice, but the Board’s 2026-27 regulatory plan lists no AI rule. Its next full meeting is December 4, 2026.
This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Sean C. Orr, M.D., who holds full editorial responsibility for its content. Illustration created with AI image tools.
References
- Utah Department of Commerce, Office of Artificial Intelligence Policy, “Doctronic” authorized pilot page. commerce.utah.gov
- Utah Office of Artificial Intelligence Policy, “Authorized Pilots.” commerce.utah.gov
- Utah Department of Commerce, news release on the Doctronic prescription renewal partnership (January 6, 2026). commerce.utah.gov
- Utah Office of Artificial Intelligence Policy and Doctronic, regulatory mitigation agreement (October 2025). commerce.utah.gov (PDF)
- Utah Office of Artificial Intelligence Policy, Doctronic outcomes report (May 2026). commerce.utah.gov (PDF)
- Utah Physicians Licensing Board, letter on the Doctronic agreement (April 20, 2026). commerce.utah.gov (PDF)
- Utah Division of Professional Licensing and Office of Artificial Intelligence Policy, response to the board (April 21, 2026). commerce.utah.gov (PDF)
- KSL, on the Utah licensing board’s letter about AI prescription renewals (April 27, 2026). ksl.com
- Matthew Perrone, Associated Press, “Is AI ready to take over your prescriptions? Doctors are wary of Utah’s automated refill program” (July 6, 2026), via WTOP. wtop.com
- Fierce Healthcare, coverage of Doctronic’s AI prescription refill pilot in Utah. fiercehealthcare.com
- Becker’s Hospital Review, Giles Bruce, on Utah’s AI prescription pilots (October 9, 2026). beckershospitalreview.com
- Doctronic, Series B announcement, Business Wire (March 24, 2026). businesswire.com
- Doctronic, company blog post on the Utah AI prescription refill program. doctronic.ai
- Hayat et al., “Toward the Autonomous AI Doctor: Quantitative Benchmarking of an Autonomous Agentic AI Versus Board-Certified Clinicians in a Real World Setting,” preprint (2025). arxiv.org
- CBS News Miami, “Florida proposes fines, monitorship, and state suspension for AI companies that abet crimes” (September 8, 2026). cbsnews.com
- FOX49, “Florida targets ‘A.I. doctors’ as local physicians urge cautious adoption” (September 9, 2026). fox49.tv
- Florida Senate, CS/SB 482 (2026), Artificial Intelligence Bill of Rights. flsenate.gov; SB 2-D (Special Session D, 2026). flsenate.gov
- Florida Senate, CS/CS/HB 527 (2026) and HB 281 (2026). flsenate.gov; flsenate.gov
- Florida Statutes, sections 458.305, 458.327, 456.065 and 456.47. 458.305; 458.327; 456.065; 456.47
- Florida Board of Medicine, meeting information. flboardofmedicine.gov; 2026-2027 annual regulatory plan. floridahealth.gov (PDF)






Leave a Reply